Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242775
Status:
COMPLETED
Last Update Posted:
2011-01-24
First Post:
2005-10-20
Brief Title:
Comparison of the EfficacySafety of Symbicort TurbuhalerSeretide Diskus 50500 µg Terbutaline Turbuhaler 04 mg
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Efficacy and Safety of Symbicort Turbuhaler 16045 µgInhalation Two Inhalations Twice Daily Plus As-needed Compared With Seretide Diskus 50500 µgInhalation One Inhalation Twice Daily Plus Terbutaline Turbuhaler 04 mgInhalation As-needed - a 6-month Randomised Double-blind Parallel-group Active Controlled Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma AHEAD
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication Seretide in the treatment of asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AHEAD | None | None | None |
| EurodraCT No 2004-004905-11 | None | None | None |